Rifampin Injection
Brand names: Rifadin Iv, Rifampin
Category: Anti-Infective
FDA status: Current · Last FDA update: Sep 18, 2026 · First posted: Feb 17, 2021 (in shortage 5 years 7 months) · 3 manufacturers, 3 listed presentations
As of Sep 18, 2026, the FDA lists Rifampin Injection as currently in shortage. Of 3 manufacturer presentations, 2 Unavailable, 1 Limited.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Rifampin, Injection, 600 mg (NDC 67457-445-60) NDC 67457-445-60 |
Mylan Institutional, a Viatris Company | Unavailable | Estimated recovery: Q4 2026 |
| Rifadin, Injection, 600 mg (NDC 0068-0597-01) NDC 0068-0597-01 |
Sanofi-Aventis U.S. LLC | Unavailable | Discontinuation of the manufacture of the drug |
| Rifampin, Injection, 600 mg (NDC 63323-351-20) NDC 63323-351-20 |
Fresenius Kabi USA, LLC | Limited | Check wholesalers for inventory |
Related medications in shortage
Other Anti-Infective medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Rifampin Injection (FDA data as of Sep 18, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Rifampin Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/rifampin-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).